Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin's lymphoma cell line via inhibition of NF-κB activity: Role of YY1 and Bcl-xL in fas resistance and chemoresistance, respectively

Journal of Immunology

Volumn 175, Issue 4, 2005, Pages 2174-2183

  Vega, Mario I ^a,b   Jazirehi, Ali R ^a   Huerta Yepez, Sara ^a,b   Bonavida, Benjamin ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,3 BIS(2 AMINOETHYL) 1 HYDROXY 2 OXOTRIAZENE; BAY 11 7085; FAS ANTIGEN; HEMAGGLUTININ; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CH 11; PROTEIN BCL XL; RITUXIMAB; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION REPRESSOR YIN YANG 1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG RESISTANCE; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIZATION;

EID: 23444459884     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.175.4.2174     Document Type: Article

References (42)

1. Ngan, B. Y., L. J. Picker, L. J. Medeiros, and R. A. Warnke. 1989. Immunophenotypic diagnosis of non-Hodgkin's lymphoma in paraffin sections: co-expression of L60 (Leu-22) and L26 antigens correlates with malignant histologie findings. Am. J. Clin. Pathol. 91: 579-583.
2. Reff, M. E., K. Carner, K. S. Chambers, P. C. Chinn, J. E. Leonard, R. Raab, R. A. Newman, N. Hanna, and D. R. Anderson. 1994. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83: 435-445.
3. Czuczman, M. S., A. Fallon, A. Mohr, C. Stewart, Z. P. Bernstein, P. McCarthy, M. Skipper, K. Brown, K. Miller, D. Wentling, et al. 2002. Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Semin. Oncol. 29: 36-40.
4. Coiffier, B. 2003. Monoclonal antibodies in the management of newly diagnosed, aggressive B-cell lymphoma. Curr. Hematol. Rep. 2: 23-29.
5. Smith, M. R. 2003. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 22: 7359-7368.
6. Demidem, A., T. Lam, S. Alas, K. Hariharan, N. Hanna, and B. Bonavida. 1997. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother. Radiopharm. 12: 177-186.
7. Alas, S., C. Emmanouilides, and B. Bonavida. 2001. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin. Cancer Res. 7: 709-723.
8. Vega, M. I., S. Huerta-Yepaz, H. Garban, A. Jazirehi, C. Emmanouilides, and B. Bonavida. 2004. Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance. Oncogene 23: 3530-3540.
9. L and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis. Mol. Cancer Ther. 2: 1183-1193.
10. L down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by rituximab. Cancer Res. 64: 7117-7126.
11. Vega, M. I., S. Huera-Yepez, A. R. Jazirehi, H. Garban, and B. Bonavida. 2004. Rituximab-mediated inhibition of the transcription represser Yin-Yang 1 (YY1) in NHL B cell lines: upregulation of Fas expression and sensitization to Fas-induced apoptosis. Blood 104: 85a (Abstr. 287).
12. Garban, H. J., and B. Bonavida. 2001. Nitric oxide inhibits the transcription represser Yin-Yang 1 binding activity at the silencer region of the Fas promoter: a pivotal role for nitric oxide in the up-regulation of Fas gene expression in human tumor cells. J. Immunol. 167: 75-81.
13. Dong, Q. G., G. M. Sclabas, S. Fujioka, C. Schmidt, B. Peng, T. Wu, M. S. Tsao, D. B. Evans, J. L. Abbruzzese, T. J. McDonnell, et al. 2002. The function of multiple IκB: NF-κB complexes in the resistance of cancer cells to taxol-induced apoptosis. Oncogene 21: 6510-6519.
14. Jazirehi, A., S. Huerta-Yepes, G. Cheng, and B. Bonavida. 2005. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-κB signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res. 65: 264-276.
15. Lee, H. H., H. Dadgostar, Q. Cheng, J. Shu, and G. Cheng. 1999. NF-κB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes. Proc. Natl. Acad. Sci. USA 96: 9136-9141.
16. Amundson, S. A., T. G. Myers, D. Scudiero, S. Kitada, J. C. Reed, and A. J. Fornace, Jr. 2000. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res. 60: 6101-6110.
17. Mounier, N., J. Briere, C. Gisselbrecht, J. F. Emile, P. Lederlin, C. Sebban, F. Berger, A. Bosly, P. Morel, H. Tilly, et al. 2003. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 101: 4279-4284.
18. Barrans, S. L., I. Carter, R. G. Owen, F. E. Daviesl, R. D. Patmore, A. P. Haynes, G. J. Morgan, and A. S. Jack. 2002. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 99: 1136-1143.
19. H-gene putative somatic mutation analysis. Blood 83: 1067-1078.
20. Ariga, A., J. Namekawa, N. Matsumoto, J. Inoue, and K. Umezawa. 2002. Inhibition of tumor necrosis factor-α-induced nuclear translocation and activation of NF-κB by dehydroxymethylepoxyquinomicin. J. Biol. Chem. 277: 24625-24630.
21. Berenbaum, M. C. 1981. Criteria for analyzing interactions between biologically active agents. Adv. Cancer Res. 35: 269-335.
22. L protein by Ets, Rel/NF-κB, STAT and AP-1 transcription factor families. Histol. Histopathol. 16: 595-601.
23. Chen, C., L. C. Edelstein, and C. Gelinas. 2000. The Rel/NF-κB family directly activates expression of the apoptosis inhibitor Bcl-xl. Mol. Cell. Biol. 20: 2687-2695.
24. Chen, Q., H. H. Lee, Y. Li, T. P. Parks, and G. Cheng. 2000. Upregulation of Bcl-x and Bfl-1 as a potential mechanism of chemoresistance, which can be overcome by NF-κB inhibition. Oncogene 19: 4936-4940.
25. Yeung, K. C., D. W. Rose, A. S. Dhillon, D. Yaros, M. Gustafsson, D. Chatterjee, B. McFerran, J. Wyche, W. Kolch, and J. M. Sedivy. 2001. Raf kinase inhibitor protein interacts with NF-KB-inducing kinase and TAK1 and inhibits NF-κB activation. Mol. Cell. Biol. 21: 7207-7217.
26. Ghosh, S., and M. Karin. 2002. Missing pieces in the NF-κB puzzle. Cell 109: S81-S96.
27. Dixit, V., and T. W. Mak. 2002. NF-κB signaling: many roads lead to Madrid. Cell 111: 615-619.
28. Karin, M., and A. Lin. 2002. NF-κB at the crossroads of life and death. Nat. Immunol. 3: 221-227.
29. Alas, S., C. P. Ng, and B. Bonavida. 2002. Rituximab modifies the cisplatinmitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma. Clin. Cancer Res. 8: 836-845.
30. L suppresses TNF-mediated apoptosis and activation of nuclear factor-κB, activation protein-1 and c-Jun N-terminal kinase. J. Interferon Cytokine Res. 20: 725-735.
31. Orlowski, R. Z., and A. S. Baldwin, Jr. 2002. NF-κB as a therapeutic target in cancer. Trends Mol. Med. 8: 385-389.
32. Garg, A., and B. B. Aggarwal. 2002. Nuclear transcription factor-κB as a target for cancer drug development. Leukemia 16: 1053-1058.
33. L expression facilitates chemotherapy-induced leukemia cell death in a SCID/NOD-Hu model. Br. J. Hematol. 112: 706-713.
34. Coiffier, B., E. Lepage, J. Briere, R. Herbrecht, H. Tilly, R. Bouabdallah, P. Morel, E. Van Den Neste, G. Salles, P. Gaulard, et al. 2002. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346: 235-242.
35. Koene, H. R., M. Kleijer, J. Algra, D. Roos, A. E. von dem Borne, and M. de Haas. 1997. FcγRIIIa- 158V/F polymorphism influences the binding of IgG by natural killer cell FcγRIIIa, independently of the FcγRIIIa-48L/R/H phenotype. Blood 90: 1109-1114.
36. Jazirehi, A. R., and B. Bonavida. 2005. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implication in chemo-sensitization and therapeutic intervention. Oncogene. 24: 2121-2143.
37. Kramer, M. H., J. Hermans, E. Wijburg, K. Philippe, E. Geelen, J. H. van Krieken, D. de Jong, E. Maartense, E. Schuuring, and P. M. Kluin. 1998. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 92: 3152-3162.
38. L protein levels. Cell Death Differ. 7: 574-586.
39. L) in human lymphomas. Br. J. Hematol. 92: 900-906.
40. L gene expression and apoptotic cell counts in follicular lymphoma. Blood 103: 695-697.
41. Reed, J. C. 1995. Bcl-2 family proteins: regulators of chemoresistance in cancer. Toxicol. Lett. 82: 155-158.
42. L can confer a multidrug resistance phenotype. Blood 86: 1903-1910.